FDA MAMMOGRAPHY QUALITY STANDARDS INTERIM REG
This article was originally published in The Gray Sheet
FDA MAMMOGRAPHY QUALITY STANDARDS INTERIM REG seeks advice on standards that should be established for mammography of patients with breast implants. Published in the Dec. 21 Federal Register, the interim final reg explains that "FDA does not believe that sufficient information is presently available with regard to special requirements for mammography of patients with breast implants." The agency asks for "comments on standards for consideration in development of the final rule."
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.